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Background: Indoor particulate matter (PM) has been linked to respiratory symptoms in former smokers with
COPD. While subjects with COPD and atopy have also been shown to have more frequent respiratory symptoms,
whether they exhibit increased susceptibility to PM as compared to their non-atopic counterparts remains unclear.
The aim of this study was to determine whether atopic individuals with COPD have greater susceptibility to PM
compared to non-atopic individuals with COPD.
Methods: Former smokers with moderate to severe COPD were enrolled (n = 77). PM2.5, PM with diameter <2.5
micrometers, was measured in the main living area over three one-week monitoring periods at baseline, 3, and
6 months. Quality of life, respiratory symptoms and medication use were assessed by questionnaires. Serum was
analyzed for specific IgE for mouse, cockroach, cat, dog and dust mite allergens. Atopy was established if at least
one test was positive. Interaction terms between PM and atopy were tested and generalized estimating equation
analysis determined the effect of PM concentrations on health outcomes. Multivariate models were adjusted for
age, sex, education, race, season, and baseline lung function and stratified by atopic status.
Results: Among atopic individuals, each 10 μg/m3 increase in PM was associated with higher risk of nocturnal
symptoms (OR, 1.95; P = 0.02), frequent wheezing (OR, 2.49; P = 0.02), increased rescue medication use (β = 0.14;
P = 0.02), dyspnea (β = 0.23; P < 0.001), higher St. George’s Respiratory Quality of Life score (β = 2.55; P = 0.01), and
higher breathlessness, cough, and sputum score (BCSS) (β = 0.44; P = 0.01). There was no association between PM
and health outcomes among the non-atopic individuals. Interaction terms between PM2.5 and atopy were statistically
significant for nocturnal symptoms, frequency of rescue medication use, and BCSS (all P < 0.1).
Conclusions: Individuals with COPD and atopy appear to be at higher risk of adverse respiratory health effects of PM
exposure compared to non-atopic individuals with COPD.
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Chronic obstructive pulmonary disease (COPD) is char-
acterized by progressive airflow limitation [1] and is a
serious public health concern as it is the third leading
cause of death in the United States [2]. COPD manifests
after extended inhalation exposure to toxic agents such* Correspondence: nhansel1@jhmi.edu
1Department of Medicine, School of Medicine, Johns Hopkins University,
Baltimore, MD 21205, USA
2Department of Environmental Health Sciences, Bloomberg School of Public
Health, Johns Hopkins University, Baltimore, MD 21205, USA
Full list of author information is available at the end of the article
© 2014 Kaji et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.as cigarette smoke [3], and continued exposure among
those with established disease is associated with worse
disease severity [1]. We have previously shown that
indoor air pollution, particularly particulate matter less
than 2.5 micron in diameter (PM2.5), even at relatively
low concentrations observed in US homes, was associ-
ated with increased respiratory symptoms and risk of
severe COPD exacerbations in former smokers with
moderate to severe COPD [4]. In addition, the presence
of allergic sensitization has also been linked to worse. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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COPD [5].
There is some evidence to suggest that allergic
sensitization to aeroallergens is associated with increased
susceptibility to the adverse health effects of PM in pa-
tients with asthma. For example, several studies suggest
that atopic individuals have worse outcomes upon ex-
posure to PM and other environmental pollutants com-
pared to non-atopics with asthma [6-8]; however these
results have not been consistent. For instance, some
studies in asthma have not shown differential health ef-
fects of PM by atopic status; [9] other studies suggest
that exposure to air pollutants is more deleterious in
non-atopic than in atopic asthmatics [10,11]. Whether
atopic individuals with COPD are more susceptible to
the effect of PM exposure compared to those without
atopy has not previously been studied. The goal of this
analysis was to investigate whether atopic individuals
with moderate to severe COPD were more susceptible




Participants and methods were previously described [4].
Briefly, 84 former smokers with COPD meeting the
following inclusion criteria were recruited from the
Baltimore area: 1) age ≥ 40 years, 2) post bronchodilator
FEV1 ≤ 80% predicted, 3) FEV1/FVC <70%, and 4) >10
pack years smoking, but having quit > 1 year prior to en-
rollment. Current non-smoking status was confirmed by
requiring an exhaled carbon monoxide level ≤6 ppm at the
time of recruitment [12]. Participants reporting a history of
asthma (n = 7) were excluded from the current analyses as
previously done in Jamieson et al. [5]. Participants provided
written informed consent and the Johns Hopkins Medical
Institutional Review Board approved the protocol.
Air quality assessment
Air sampling was performed for one week at baseline, 3
and 6 months in the main living area, identified as a
room, other than the bedroom, where the participant re-
ported spending the most time and the bedroom. Indoor
air sampling for PM2.5 and nitrogen dioxide (NO2) was
conducted as described previously [9]. The limit of de-
tection (LOD) for PM2.5 was 0.64 μg/m
3.
Clinical evaluation
Clinic visits occurred between day 4 and 7 of the air
monitoring period at baseline, 3 and 6 months. Validated
questionnaires assessed quality of life (St. George’s
Respiratory Questionnaire (SGRQ)) [13], dyspnea (Medical
Research Council (MRC) dyspnea scale) [14], and respira-
tory health. Presence of cough or phlegm was determinedby a positive response to either of the following questions
from the American Thoracic Society Division of Lung dis-
ease (ATS-DLD) Questionnaire [15]: “Do you usually have
a cough?” or “Do you usually bring up phlegm from your
chest” at each visit and was dichotomized to “yes” or “no.”
Subjects reported whether they experienced wheeze in the
last four weeks and responses were dichotomized to “fre-
quent” if they reported symptoms almost every day, several
days a week, or a few days a month and “infrequent” if they
responded only with respiratory infections, or not at all.
Nocturnal symptoms defined as coughing or breathing that
disturbs sleep was dichotomized to “yes” or “no”. Fre-
quency of rescue medication use (0, 1, 2, 3 or >4 times
daily) and symptoms as assessed by Breathlessness, Cough
and Sputum Score (BCSS) [16] were assessed by daily
diary. Responses were averaged over each one-week moni-
toring period. Spirometry, before and after albuterol, was
performed according to American Thoracic Society (ATS)
criteria [17,18]. Serum was analyzed for specific IgE by
ImmunoCAP (Phadia, ThermoFisher, USA) for mouse,
cockroach, cat, dog and dust mite allergens. A participant
was considered atopic if at least one test was at or above
the level of detection (0.1 kUA/L).
Exacerbations over the duration of study were assessed
by questionnaires at each clinic visit and by monthly
telephone calls. Any exacerbation was defined as wors-
ening respiratory symptoms requiring antibiotics, oral
steroids or an acute care visit. Severe exacerbations were
defined as worsening respiratory symptoms leading to
an Emergency department (ED) visit or hospitalization.
Statistical analysis
Descriptive statistics were analyzed using likelihood-
ratio tests and t-tests, as appropriate. At each time point,
the PM2.5 concentrations were used as exposure vari-
ables in generalized estimating equations models [15], in
order to account for the correlation arising from re-
peated measures of the outcomes over time; adjusting for
age, sex, education, season (spring/summer vs. fall/winter)
and pre-bronchodilator % predicted FEV1. In sensitivity
analysis, we also included the use of inhaled corticoste-
roids (ICS) as a confounding variable. Interaction terms
were used in the final models to formally test for interac-
tions between PM2.5 and atopy. Because significant inter-
actions between PM2.5 and atopy were identified, analyses
investigating the association between PM2.5 and COPD
outcomes were stratified by atopic status. To evaluate the
effect of PM2.5 on respiratory health, continuous and bin-
ary outcomes were analyzed using linear and logistic re-
gression models, respectively, with PM2.5 included as a
continuous predictor. All models with a generalized esti-
mating equations approach assumed exchangeable corre-
lations. The primary analyses included effects of the main
living area as this was found to be the most important area
Table 1 Baseline participant characteristics





Age, mean (SD) 69.3 (7.1) 69.7 (7.1) 0.86
Gender, % male 63 57 0.60
Race, (%)
Caucasian 89 83
0.71Black/African American 9 13
Other 2 4
Education, (%)
< High School 19 22
0.63
High School 24 9
Some College 30 39
Bachelor’s Degree 13 13
At least some Graduate School 15 17
Smoking History, mean (SD)
Pack Years 56.8 (28.4) 60.7 (31.0) 0.60
Last Cigarette (Years Since) 13.0 (9.7) 13.4 (8.0) 0.85
Baseline Health Status
Post Bronchodilator FEV1% predicted,
mean (SD)
52.4 (16.11) 51.9 (17.29) 0.89
Pre FEV1/FVC 0.50 (0.10) 0.52 (0.10) 0.45
Post FEV1/FVC 0.51 (0.10) 0.54 (0.11) 0.28
Bronchodilator reversibility, (%) 31.5 30.4 0.93
Chronic Bronchitis (%) 39 35 0.73
Emphysema (%) 57 70 0.32
SGRQ, mean (SD) 38.6 (17.6) 42.0 (20.7) 0.47
MMRC, mean (SD) 2.6 (1.0) 2.5 (1.2) 0.63
Medication list, (%)
Long acting beta agonist (LABA) 8 4 0.61
Inhaled Corticosteroids (ICS) 19 5 0.12
ICS/LABA combination 44 65 0.10
Long acting muscarinic antagonist 37 43 0.60
Nasal steroids 6 9 0.61
Leukotriene modifiers 8 9 0.88
Theophylline 2 9 0.16
Antihistamine 2 9 0.16
Comorbidities, (%)
Congestive heart failure 6 9 0.61
Diabetes 19 26 0.45
Cancer 19 22 0.74
Myocardial infarction 11 22 0.22
Hypertension 59 61 0.90
Kidney disease 2 0 0.51
Please note some of the data from the above table were previously published
in a manuscript from the CODE cohort [5].
BCSS = Breathlessness, Cough, and Sputum Scale.
SGRQ = St. George’s Respiratory Questionnaire.
MMRC =Modified Medical Research Council.
FEV1 = Forced expiratory volume in 1 second.
FVC = Forced vital capacity.
SD = Standard deviation.
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tion of interactions with atopy and associations between
NO2 and bedroom PM2.5 with health outcomes were in-
cluded as secondary analyses.
All analyses were performed with StataSE statistical
software, version 11.0 (Stata Corp, College Station, TX).
A P value less than 0.05 was considered statistically sig-
nificant for main effects and a P value less than 0.10 was
considered statistically significant for interactions for
modestly sized populations, as previously done and rec-
ommended by Selvin et al. [19].
Results
Baseline participant characteristics and pollutant
concentrations
All participants (n = 77) had moderate or severe COPD
with a mean baseline post-bronchodilator FEV1 % pre-
dicted of 52.3%. As previously published, a third (30%)
of individuals were atopic (17 tested positive to cock-
roach, 16 to house dust mite, 7 to dog, 6 to cat and 1 to
mouse allergen). At baseline, atopic participants with
COPD were significantly more likely to report the presence
of wheeze, nocturnal cough, and health care utilization in
the previous one year compared to non-atopic subjects [5].
There was no difference in reported baseline quality of life
(SGRQ score), dyspnea (MMRC score), or prevalence of
common comorbidities (Table 1).
Atopic and non-atopic participants reported spending
similar amounts of time indoors (90% and 92%, respect-
ively). At baseline, the median PM2.5 (IQR) concentra-
tions tended to be higher in homes of atopic individuals
(12.3 (4.7, 26.8) μg/m3 vs. 9.0 (2.6, 29.3) μg/m3, p = 0.07).
There were no significant differences in regards to type
of housing, heating, or cooking or presence of air nico-
tine or report of other smokers in the home between
those with and without atopy (data not shown).
Association of indoor pollutant concentrations and
respiratory health
In bivariate analyses, increasing PM2.5 concentrations
in the main living area were associated with increased
frequency of wheeze, rescue medication use, nocturnal
symptoms and worse quality of life (SGRQ) among
atopic individuals (Table 2). Among the non-atopic indi-
viduals, there were no statistically significant associations
between PM and respiratory outcomes.
Similarly, after adjustment for confounders in multi-
variate analyses, indoor PM2.5 in the main living area
was significantly associated with respiratory health out-
comes among atopic individuals but not among non-atopic
individuals (Table 3) (Figure 1). Specifically, among atopic
individuals, increasing PM2.5 concentrations were signifi-
cantly associated with increased risk of nocturnal symp-
toms (OR 1.95, p = 0.02), BCSS scores (β = 0.44, p = 0.01)
Table 2 Bivariate association of indoor pollutant concentrations* and respiratory health
Bivariate analysis
Non-atopic participants (n = 54) Atopic participants (n = 23)
β p 95% CI β p 95% CI
MMRC (dyspnea) 0.11 0.31 [−0.11,0.33] 0.21 0.01 [0.06,0.37]
Rescue medication use 0.06 0.49 [−0.11,0.24] 0.18 0.03 [0.02,0.34]
BCSS −0.28 0.13 [−0.65,0.09] 0.32 0.09 [−0.05,0.69]
SGRQ 1.04 0.47 [−1.77,3.85] 2.15 0.05 [0.03,4.27]
OR p 95% CI OR p 95% CI
Wheeze 1.38 0.14 [0.90,2.11] 2.25 0.01 [1.22,4.14]
Nocturnal symptoms 1.00 0.98 [0.55,1.80] 1.76 0.04 [1.02,3.01]
Cough 0.76 0.27 [0.46,1.24] 1.11 0.50 [0.82,1.51]
Phlegm 1.09 0.67 [0.72,1.66] 1.15 0.37 [0.84,1.57]
Severe exacerbations 0.89 0.81 (0.35, 2.28) 1.27 0.21 (0.87, 1.83)
BCSS = Breathlessness, Cough, and Sputum Scale.
SGRQ = St. George’s Respiratory Questionnaire.
MMRC =Modified Medical Research Council.
*ORs and coefficients represent difference in stated outcomes for every 10 point change in PM2.5.
Bold values represent statistically significant associations (p <0.05).
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p = 0.02), with atopy significantly modifying the effect
of PM exposure (all p interaction values < 0.1). In addition,
a 10 μg/m3 increase in PM2.5 concentrations was also asso-
ciated with increased dyspnea (higher MMRC score,
β = 0.23, p < 0.001), worse quality of life (higher SGRQ
score, β = 2.55, p = 0.01) and higher likelihood of having
frequent wheeze (OR = 2.49, p = 0.02) among atopic indi-
viduals. PM2.5 was not significantly associated with health
outcomes in non-atopic individuals (Table 3). Adjusting
for the use of ICS did not substantially change the results
(data not shown).
Though, bedroom PM2.5 concentrations were not as-
sociated with COPD outcomes in main effect analysesTable 3 Multivariate analyses of association of indoor polluta
Multivariate analysis
Non-atopic participants (n = 54)
β p 95% C
MMRC 0.08 0.52 [−0.16, 0.
Rescue medication use 0.01 0.90 [−0.18, 0.
BCSS −0.30 0.13 [−0.70, 0.
SGRQ 1.06 0.45 [−1.67, 3.
OR p 95% C
Frequent wheeze 1.16 0.56 [0.71, 1.8
Nocturnal symptoms 0.60 0.19 [0.29, 1.2
Cough 0.70 0.20 [0.41, 1.2
Phlegm 1.25 0.37 [0.77, 2.0
Severe exacerbations 0.87 0.79 [0.31, 2.4
BCSS = Breathlessness, Cough, and Sputum Scale.
SGRQ = St. George’s Respiratory Questionnaire.
MMRC =Modified Medical Research Council.
*ORs and coefficients represent difference in stated outcomes for every 10 point ch
Bold values represent statistically significant assiciations (p <0.05).previously published [4], we found statistically significant
interactions between bedroom PM2.5 and atopy for both
nocturnal respiratory symptoms and risk for severe exac-
erbations. Specifically, the relationship between bedroom
PM2.5 concentrations and nocturnal respiratory symp-
toms differed by atopic status (OR 1.05, p = 0.32 for
atopic vs. OR 0.94, p = 0.21 non-atopic) as did the risk
for severe exacerbations (OR 1.2, p = 0.04 for atopic vs.
OR 0.81, p = 0.15 for non-atopic, interaction p-value for
both comparisons <0.1). There were no statistically sig-
nificant interactions between bedroom PM2.5 and atopy
for other outcomes.
A 20 point increase in NO2 concentrations in the main
living was more likely to be associated with increasednt concentrations and respiratory health*
Atopic participants (n = 23)
int(p)
I β p 95% CI
32] 0.23 <0.001 [0.09, 0.34] 0.62
20] 0.14 0.02 [0.02, 0.26] <0.001
09] 0.44 0.01 [0.11, 0.76] 0.08
80] 2.55 0.01 [0.69, 4.41] 0.44
I OR p 95% CI
8] 2.49 0.02 [1.17, 5.30] 0.17
7] 1.95 0.02 [1.09, 3.48] 0.03
0] 1.26 0.23 [0.86, 1.85] 0.28
5] 1.32 0.15 [0.91, 1.93] 0.79
2] 2.12 0.03 [1.06, 4.27] 0.63
ange in PM2.5.
Figure 1 Differential health effects of PM on respiratory health
among atopic and non-atopic former smokers with COPD.
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compared to non-atopic individuals (OR 0.67, p = 0.35),
p-interaction 0.09. There were no significant interactions
between bedroom or main living area NO2 concentra-
tions and atopy for the remaining health outcomes (data
not shown).
Discussion
To our knowledge, this is the first study investigating
whether the presence of atopy modifies the effect of
PM exposure on respiratory health in individuals with
COPD. It has been previously shown that atopy is preva-
lent in populations of COPD and is linked to worse
respiratory symptoms [20,21]; and that higher PM ex-
posure is associated with worse respiratory outcomes in
former smokers with COPD [4]. Our results show that
atopic individuals with COPD may be more susceptible
to the effects of PM exposure than non-atopic individuals.
In particular, higher indoor PM concentration was linked
to increased daytime and nocturnal respiratory symptoms
and more frequent rescue medication use among atopic
individuals but not among non-atopic individuals. This
data suggest that atopic patients living with COPD may
exhibit a differential response to particulate matter com-
pared to their non-atopic counterparts.
Studies evaluating whether allergic sensitization to
aeroallergens is associated with increased susceptibility
to the adverse health effects of pollutant exposure in
patients with other chronic lung diseases, such as
asthma have been conducted however results have been
inconsistent. Some epidemiologic studies, similar to our
current study in COPD, have found that atopic individ-
uals with asthma may be more susceptible to the effects
of PM. For example, in a small study with 19 asthmatic
children, Delfino et al. showed that PM2.5 exposure was
associated with a larger reduction in lung function inchildren allergic to indoor allergens as compared to those
that were non-allergic [22]. It has also been suggested
that tobacco smoke exposure is linked to worse respiratory
symptoms in atopic children compared to non-atopic chil-
dren with asthma [23]. In regards to NO2, epidemiological
and experimental studies also suggest that atopic status
may modify susceptibility to NO2 exposure in individuals
with asthma, but the results have also been inconsistent
[24]. Some studies suggest that there is no differential
effect of air pollution exposure on atopic or non-atopic
individuals [9] and others have shown that non-atopic
individuals may be more susceptible [7,25-27].
There are several potential mechanisms by which the
presence of atopy may increase susceptibility to PM ex-
posure. For example, several studies have shown that
PM acts as a carrier to some aeroallergens (e.g., cat, dog,
birch pollen, and house dust mite allergen) [28,29].
Therefore, the link between higher PM concentrations
and health effects may not be due to the direct effects of
particulate matter but to the associated increased allergen
exposure in sensitized individuals. Furthermore, PM may
work as an adjuvant with allergens to incite inflammatory
pathways [30]. There are several human and animal experi-
mental studies which support a possible synergistic effect
between air pollution and allergen exposure. Individuals
with asthma have been shown to experience a greater drop
in lung function upon exposure to allergen and air pollut-
ants compared to those exposed to allergen without air
pollutants [6,31]. Alberg et al. showed that a combined
dosage of PM and Ova allergen injected into mice lead to
higher serum anti-Ova IgE concentrations compared with
an injection of the allergen Ova alone [32].
In addition to PM being a surrogate for allergen ex-
posure or being linked to a heightened response to aller-
gen exposure, those with atopy may have an inherent
predisposition to a heightened response to PM itself.
Atopy has been linked to increased underlying eosino-
philic airway and systemic inflammation as well as in-
creased bronchial hyper-responsiveness (BHR) even in
individuals without asthma [33-35]. This underlying eo-
sinophilic inflammation or increased BHR may predis-
pose individuals to the adverse health effects of pollutant
exposure. For example, ozone exposure worsened BHR
in a dose dependent fashion in atopic guinea pigs, but
did not induce airway hyper-responsiveness in the non-
atopic guinea pigs [36]. Being an observational study, we
were unable to identify mechanistic underpinnings for
our associations which merits further examination.
The moderate size of the study population limits our
ability to detect statistically significant interactions and
raises the possibility of type II error, which underscores
the need to test our hypotheses in future studies. Despite
this, we found statistically significant interactions for sev-
eral outcomes and a consistent trend of stronger adverse
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atopic individuals lending validity to our results that atopic
individuals with COPD are more susceptible the effects of
PM than non-atopic individuals. Allergen concentrations
on PM filters were not available and therefore we were un-
able to determine whether higher allergen concentrations
in PM were linked to worse health outcomes. Furthermore,
our assessment of atopic status was limited to perennial
allergens and we were not able to investigate whether in-
creasing number of allergic sensitizations or specific sensi-
tizations portends greater risk to the adverse health effects
of PM on patients with COPD.
Conclusion
Our study demonstrates that increasing particulate matter
concentrations are more strongly associated with worsen-
ing respiratory symptoms for atopic COPD patients than
for non-atopic COPD patients. As this may be the first
study to look at the importance of allergic sensitization as
a modifier of particulate matter as it pertains to COPD,
very little clinical guidance currently exists for the differen-
tial management of atopics versus non-atopics with COPD.
Additional research is needed to support the findings of
this study in a larger sample size in order to further
characterize the role of an allergic phenotype in COPD
and to determine strategies to reduce PM and improve
outcomes in this important population.
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